Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan DOI Creative Commons
Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura‐Kimura

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: April 29, 2024

Abstract Background The magnitude and durability of cell-mediated immunity in older severely frail individuals following coronavirus disease 2019 (COVID-19) vaccination remain unclear. A controlled immune response could be the key to preventing severe COVID-19; however, it is uncertain whether induces an anti-inflammatory cellular response. To address these issues, this 48-week-long prospective longitudinal study was conducted. total 106 infection-naive participants (57 long-term care facility [LTCF] residents [median age; 89.0 years], 28 outpatients 72.0 21 healthcare workers 51.0 years]) provided peripheral blood mononuclear cell (PBMC) samples for assessment spike-specific T-cell responses before primary vaccination, 24 weeks after three months booster vaccination. CD4 + acute respiratory syndrome 2 spike protein were examined by measuring interferon (IFN)-γ, tumor necrosis factor (TNF), interleukin (IL)-2, IL-4, IL-6, IL-10 levels secreted from peptide-stimulated PBMCs participants. Results LTCF exhibited significantly lower IFN-γ, TNF, IL-2, IL-6 than Booster increased IL-2 comparable those workers, whereas IFN-γ TNF remained workers. not different initial values but all subgroups. Multivariate analysis showed that age negatively associated with levels. pro-inflammatory cytokines, including positively correlated humoral responses, not. Conclusions Older may exhibit diminished COVID-19 compared general population. single adequately enhance a level Furthermore, induce only also response, potentially mitigating detrimental hyperinflammation.

Language: Английский

2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN) DOI Creative Commons
Danuta M. Skowronski,

Yuping Zhan,

Samantha E Kaweski

et al.

Eurosurveillance, Journal Year: 2024, Volume and Issue: 29(7)

Published: Feb. 15, 2024

The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% 33–71) than 5a.2a (67%; 48–80), and lowest A(H3N2) (40%; 5–61). Omicron XBB.1.5 protected comparably well, with VE 47% 21–65) medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% 28–85).

Language: Английский

Citations

39
Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan DOI Creative Commons
Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura‐Kimura

et al.

Immunity & Ageing, Journal Year: 2024, Volume and Issue: 21(1)

Published: June 22, 2024

Abstract Background The magnitude and durability of cell-mediated immunity in older severely frail individuals following coronavirus disease 2019 (COVID-19) vaccination remain unclear. A controlled immune response could be the key to preventing severe COVID-19; however, it is uncertain whether induces an anti-inflammatory cellular response. To address these issues, a 48-week-long prospective longitudinal study was conducted. total 106 infection-naive participants (57 long-term care facility [LTCF] residents [median age; 89.0 years], 28 outpatients 72.0 21 healthcare workers 51.0 years]) provided peripheral blood mononuclear cell (PBMC) samples for assessment spike-specific PBMC responses before primary vaccination, 24 weeks after three months booster vaccination. Cellular acute respiratory syndrome 2 spike protein were examined by measuring interferon (IFN)-γ, tumor necrosis factor (TNF), interleukin (IL)-2, IL-4, IL-6, IL-10 levels secreted from peptide-stimulated PBMCs participants. Results LTCF exhibited significantly lower IFN-γ, TNF, IL-2, IL-6 than Booster increased IL-2 comparable those workers, whereas IFN-γ TNF remained workers. not different initial values but all subgroups. Multivariate analysis showed that age negatively associated with levels. pro-inflammatory cytokines, including positively correlated humoral responses, not. Conclusions Older may exhibit diminished COVID-19 compared general population. single adequately enhance level Furthermore, induce only also response, potentially mitigating detrimental hyperinflammation.

Language: Английский

Citations

2
Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021–February 2022 DOI Creative Commons
Yangyang Deng,

Y. Kim,

Anna Bratcher

et al.

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 12(1)

Published: Dec. 23, 2024

Abstract Background Understanding the risk of hospitalization from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can guide effective public health interventions and severity assessments. This study calculated infection–hospitalization ratios (IHRs) infection–case (ICRs) to understand relationship between SARS-CoV-2 infections, cases, hospitalizations among different age groups during periods Delta Omicron variant predominance. Methods After calculating antinucleocapsid antibody seroprevalence using residual commercial laboratory serum specimens, were computed: (1) IHRs disease 2019 data (2) ICRs Centers for Disease Control Prevention surveillance data. Ratios across (0–17, 18–49, 50–69, ≥70 years) time (September–December 2021 [Delta] December 2021–February 2022 [Omicron]). Results Pediatric increased 76.7 258.4 Omicron. Adult ranged 3.0 (≥70 21.6 (18–49 10.0 119.1 The pediatric ICR was lower period (2.7) compared with (3.7). (Delta: 1.1 [18–49 years] 2.1 [70+ years]; Omicron: 2.2 [>70+ 2.9 [50–69 years]) than both periods. Conclusions All exhibited a proportion associated in period; each older group. A reported cases all groups.

Language: Английский

Citations

1
Clinical utility and interpretive guidance for SARS-CoV-2 serological testing DOI
Muhammad Morshed, Agatha N. Jassem, Danielle Luk

et al.

Clinical Microbiology Newsletter, Journal Year: 2023, Volume and Issue: 45(24), P. 209 - 218

Published: Dec. 1, 2023

Language: Английский

Citations

1
Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in Canada DOI Creative Commons
Rafael N. Miranda, Alison E. Simmons, Michael Li

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 8, 2024

ABSTRACT Background: With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for ongoing COVID-19 vaccination programs are increasingly important. We assessed cost-effectiveness of programs, where eligibility is defined by combinations age chronic medical conditions, including a strategy similar to current Canadian recommendations, from health system societal perspectives. Methods: used static, individual-based probabilistic model simulating medically attended population 1 million people followed over 15-month time period estimate costs 2023 dollars, quality-adjusted life years (QALYs), incremental cost- effectiveness ratios (ICERs), discounted at 1.5%. epidemiology, characteristics, were based on most recently available data. Results: Annual adults aged 65 older consistently emerged as effective intervention, with ICERs less than $50,000 per QALY compared no range assumptions. Adding second dose or expanding include younger groups, those higher risk due generally resulted greater QALY. Shifting timing better align periods high case occurrence could result biannual being cost-effective strategy. Conclusions: may be when focused groups disease. Optimal improve various strategies.

Language: Английский

Citations

0
Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan DOI Creative Commons
Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura‐Kimura

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: April 29, 2024

Abstract Background The magnitude and durability of cell-mediated immunity in older severely frail individuals following coronavirus disease 2019 (COVID-19) vaccination remain unclear. A controlled immune response could be the key to preventing severe COVID-19; however, it is uncertain whether induces an anti-inflammatory cellular response. To address these issues, this 48-week-long prospective longitudinal study was conducted. total 106 infection-naive participants (57 long-term care facility [LTCF] residents [median age; 89.0 years], 28 outpatients 72.0 21 healthcare workers 51.0 years]) provided peripheral blood mononuclear cell (PBMC) samples for assessment spike-specific T-cell responses before primary vaccination, 24 weeks after three months booster vaccination. CD4 + acute respiratory syndrome 2 spike protein were examined by measuring interferon (IFN)-γ, tumor necrosis factor (TNF), interleukin (IL)-2, IL-4, IL-6, IL-10 levels secreted from peptide-stimulated PBMCs participants. Results LTCF exhibited significantly lower IFN-γ, TNF, IL-2, IL-6 than Booster increased IL-2 comparable those workers, whereas IFN-γ TNF remained workers. not different initial values but all subgroups. Multivariate analysis showed that age negatively associated with levels. pro-inflammatory cytokines, including positively correlated humoral responses, not. Conclusions Older may exhibit diminished COVID-19 compared general population. single adequately enhance a level Furthermore, induce only also response, potentially mitigating detrimental hyperinflammation.

Language: Английский

Citations

0